SLC5A2 and fatty liver disease: Overall, SGLT2 inhibitors show promising efficacy in patients with MASH by reducing hepatic lipid accumulation, but more histological evidence is needed to confirm the benefits of SGLT2 inhibitors in hepatic steatosis.